Early diagnosis and predictors of malignancy of adnexal masses.
OBJECTIVE
Ovarian cancer is an important cause of death among women with a malignant gynecological tumor. Cure rates for the disease at an early stage are around 80-90%, but survival is only 50% as the majority of women already show advanced disease upon diagnosis. The combination of gynecological examination, ultrasonography, and systemic tumor marker assay is considered to be a good strategy for the early diagnosis of ovarian neoplasia.


RESULTS
Today, new technologies such as ultrasonography and tumor marker assay have increased the diagnosis rate for adnexal masses. These non-invasive methods, however, frequently do not distinguish benign conditions from malignant ones, which results in unnecessary surgery. Transvaginal ultrasonography is useful for diagnosing adnexal masses, but benign and malignant adnexal masses can present similar morphological characteristics. Combination with color Doppler ultrasonography and/or tumor markers may improve the accuracy of the method. Gene-expression array, proteomics and mathematical models form new approaches, but proper prospective studies are needed to validate them.


CONCLUSIONS
The techniques of pelvic examination, ultrasonography, color Doppler ultrasonography, and tumor markers can be indicated for the diagnosis of ovarian cancer. The differentiation between benign and malignant ovarian tumor is, however, a clinical challenge. Until better diagnostic methods become available, patients and their physicians can use these techniques to decide on management.
Murta
Eddie F C
EF
Discipline of Gynecology and Obstetrics, Federal University of Triângulo Mineiro, Uberaba, Minas Gerais, Brazil. eddiemurta@mednet.com.br
Nomelini
Rosekeila S
RS
D000291:Adnexal Diseases / Q000175:diagnosis* / Q000235:genetics; D014408:Biomarkers, Tumor / Q000097:blood; D005260:Female; D020869:Gene Expression Profiling; D006801:Humans; D008403:Mass Screening; D008954:Models, Biological; D020411:Oligonucleotide Array Sequence Analysis; D010051:Ovarian Neoplasms / Q000175:diagnosis* / Q000235:genetics; D011379:Prognosis; D040901:Proteomics
D014408:Biomarkers, Tumor